ライフサイエンスコーパス: lipopolysaccharide-binding protein

1 se:mannitol test, plasma zonulin, and plasma lipopolysaccharide-binding protein).

2 rred in reverse from MD-2 to CD14 but not to lipopolysaccharide-binding protein.

3 Levels of the serum opsonin lipopolysaccharide-binding protein also significantly in

4 prevents interaction of endotoxin with both lipopolysaccharide binding protein and CD14, thereby blo

5 Subgroup analyses on patients with increased lipopolysaccharide binding protein and systemic vascular

6 ity of two other proteins known to bind LPS, lipopolysaccharide-binding protein and bactericidal/perm

7 dging endotoxin (E) recognition initiated by lipopolysaccharide-binding protein and CD14 to TLR4 acti

8 There was reduction in serum IL-6 and lipopolysaccharide-binding protein and increased butyrat

9 For all aggregates, lipopolysaccharide-binding protein and soluble CD14-indu

10 oxin from an aggregated form to CD14 via the lipopolysaccharide-binding protein and then to MD-2.

11 Serum levels of APPs, soluble CD14, lipopolysaccharide binding protein, and C-reactive prote

12 nding of LPS to its plasma carrier molecule, lipopolysaccharide binding protein, and decreased bindin

13 as measured by soluble CD14, soluble CD163, lipopolysaccharide binding protein, and microbial 16s ri

14 ed with higher systolic blood pressure, TGs, lipopolysaccharide-binding protein, and lower HDL choles

15 plasma concentrations of serum amyloid A and lipopolysaccharide-binding protein, and the expression o

16 Lipopolysaccharide-binding protein augmented the release

17 of peripheral blood mononuclear cells, since lipopolysaccharide-binding protein augments release in a

18 evels of C-X-C chemokine ligand 10 (CXCL10), lipopolysaccharide-binding protein, C-reactive protein,

19 Chemokine (C-C motif) ligand 2, lipopolysaccharide-binding protein, C-reactive protein,

20 n and protein-protein interactions involving lipopolysaccharide-binding protein, CD14, MD-2, and Toll

21 n and protein-protein interactions involving lipopolysaccharide-binding protein, CD14, MD-2, and Toll

22 ion, a single nucleotide polymorphism in the lipopolysaccharide binding protein coding region that wa

23 erleukin-6, tumor necrosis factor-alpha, and lipopolysaccharide binding protein decreased significant

24 rphisms in the proximal coding region of the lipopolysaccharide binding protein gene and to determine

25 ein (PLTP) are members of the lipid transfer/lipopolysaccharide binding protein gene family.

26 As a member of the lipid-transfer lipopolysaccharide-binding protein gene family, phosphol

27 The recent characterization of lipopolysaccharide binding protein (LBP) and bactericida

28 n (lipopolysaccharide, LPS) are amplified by lipopolysaccharide binding protein (LBP) and CD14, resul

29 f phospholipids, apolipoprotein A-I (apoAI), lipopolysaccharide binding protein (LBP) and Factor H-re

30 Plasma lipopolysaccharide binding protein (LBP) and intestinal

31 dal/permeability inducing protein (BPI), and lipopolysaccharide binding protein (LBP) are members of

32 inal fatty acid binding protein (I-FABP) and lipopolysaccharide binding protein (LBP) did not differ

33 Lipopolysaccharide binding protein (LBP) function is dep

34 tinal permeability was assessed by measuring lipopolysaccharide binding protein (LBP) in plasma and z

35 elevated levels of soluble CD14 (sCD14) and lipopolysaccharide binding protein (LBP) in the plasma d

36 Lipopolysaccharide binding protein (LBP) is a plasma pro

37 flammatory and anti-inflammatory markers and lipopolysaccharide binding protein (LBP) plasma as well

38 genomic screen, we found that expression of lipopolysaccharide binding protein (LBP), a member of th

39 d biomarkers: serum and fecal zonulin; serum lipopolysaccharide binding protein (LBP), Alpha-1-acid g

40 x of complement activation; plasma levels of lipopolysaccharide binding protein (LBP), an acute phase

41 els of APPs, including soluble CD14 (sCD14), lipopolysaccharide binding protein (LBP), and C-reactive

42 trations of HDL-bound serum amyloid A (SAA), lipopolysaccharide binding protein (LBP), apolipoprotein

43 nase plasminogen activator receptor (suPAR), lipopolysaccharide binding protein (LBP), beta-D-glucan

44 Complement C5A anaphylatoxin (C5A), lipopolysaccharide binding protein (LBP), C-reactive pro

45 nd plasma levels of an acute phase reactant, lipopolysaccharide binding protein (LBP), to clinical ou

46 Conversely, serum lipopolysaccharide-binding protein (LBP) (b = - 0.1, p <

47 Lipopolysaccharide-binding protein (LBP) and CD14 play k

48 Serum levels of lipopolysaccharide-binding protein (LBP) and IL-10 were

49 by two lipid-binding serum proteins known as lipopolysaccharide-binding protein (LBP) and soluble CD1

50 o assess two bacterial endotoxin biomarkers, lipopolysaccharide-binding protein (LBP) and soluble CD1

51 ieved to involve the interaction of LPS with lipopolysaccharide-binding protein (LBP) in the serum an

52 Plasma endotoxin and lipopolysaccharide-binding protein (LBP) levels were mea

53 actors, and the CD4/CD8 T-cell ratio, higher lipopolysaccharide-binding protein (LBP) was associated

54 In this study, we examined the role of lipopolysaccharide-binding protein (LBP), a protein impo

55 d biopsies, stool analysis, cognition, serum lipopolysaccharide-binding protein (LBP), and duodenal a

56 hanges in the gut integrity markers zonulin, lipopolysaccharide-binding protein (LBP), and intestinal

57 dotoxin (E) with endotoxin-binding proteins (lipopolysaccharide-binding protein (LBP), CD14, and MD-2

58 negative bacteria require the interaction of lipopolysaccharide-binding protein (LBP), CD14, Toll-lik

59 Levels of soluble CD14 (sCD14), human lipopolysaccharide-binding protein (LBP), immunoglobulin

60 al/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP), which are cent

61 of endotoxin have revealed the importance of lipopolysaccharide-binding protein (LBP)-dependent extra

62 ctive protein (CRP), Procalcitonin (PCT) and Lipopolysaccharide-binding protein (LBP).

63 dicated by the regularisation of clotting by lipopolysaccharide-binding protein (LBP).

64 udens-1 [ZO-1]) and microbial translocation (lipopolysaccharide binding protein [LBP] and soluble com

65 le cluster of differentiation 14 [sCD14] and lipopolysaccharide binding protein [LBP]) compared to co

66 l translocation and gut barrier dysfunction (lipopolysaccharide binding protein [LBP], zonulin, and i

67 te that albumin is an essential component of lipopolysaccharide binding protein- (LBP) and sCD14-depe

68 ptoglobin-HPT; Insulin-like growth factor 1; Lipopolysaccharide binding protein-LBP; Mannose-binding

69 protein 1 levels (r = 0.396, P = .0002) and lipopolysaccharide binding protein levels (r = 0.25, P =

70 Phospholipid transfer protein (PLTP) and lipopolysaccharide-binding protein (LPB) are lipid trans

71 tein (LBP) are members of the lipid transfer/lipopolysaccharide binding protein (LT/LBP) family of pr

72 ndeed, both TLR4 and LY96, which encodes the lipopolysaccharide binding protein (MD-2), were upregula

73 on of IL-6 messenger RNA (mRNA) in liver and lipopolysaccharide binding protein mRNA in the liver and

74 trations of gut-derived hormones, incretins, lipopolysaccharide-binding protein, or other markers of

75 or-alpha (P<.05), interleukin-6 (P<.05), and lipopolysaccharide binding protein (P<.05) levels were a

76 on rate (P<.05), interleukin-6 (P<.005), and lipopolysaccharide binding protein (P<.05).

77 the release of secretory phospholipase A2 or lipopolysaccharide-binding protein (P > .05).

78 , quality of life, cognition, serum IL-6 and lipopolysaccharide-binding protein, plasma/stool short-c

79 lavage co-precipitates CD14, a cell surface lipopolysaccharide-binding protein that is involved in i

80 ration rate and plasma renin, noradrenaline, lipopolysaccharide binding protein, troponin T, and brai

81 a, interleukin 6 (IL-6), interleukin 10, and lipopolysaccharide binding protein were assessed preoper

82 Originally identified as a lipopolysaccharide binding protein with Gram-negative ba